Platform assets sale AgBiome recently divested its platform assets to Ginkgo Bioworks, including a vast repository of strains and gene sequences. This suggests a potential opportunity to position alternative microbial discovery or collaboration solutions for crop protection through new partners or internal capabilities.

Howler EVO launch The market introduction of Howler EVO fungicide indicates ongoing product development and a push into advanced disease control solutions. This presents a sales angle for complementary crop protection products, application services, or tiered performance data to support adoption.

Headcount changes Significant workforce reductions in 2023 imply potential capacity constraints and a shift in strategic focus. Opportunities may exist to provide specialized outsourced services, R&D collaboration, or support in commercialization and field trials to fill gaps.

Strategic partnerships Past collaborations with Gore & Associates to enhance microbial production signal openness to external manufacturing and scale-up partnerships. This could translate into opportunities for contract development and manufacturing, supply chain optimization, or joint go-to-market arrangements.

Revenue and funding profile With modest revenue and substantial funding, AgBiome may be seeking strategic partnerships to accelerate product reach and monetize its assets. Prospects include licensing, co-development deals, or investment-backed commercialization support for existing and upcoming microbial products.